Effect of Semaluptide on renal function in patients with type II diabetes mellitus

Patients with type II diabetes have a high risk of diabetic nephropathy. Not long ago, scientific researchers investigated the effect of semaluptide on renal function in patients with type II diabetes.

This scientific study was the post event analysis of suppine1-5, suppine6 and suppine7 scientific studies, including 8416 patients with type II diabetes who received intradermal injection of 0.5mg and 1.0mg of semaluptide or control (including active treatment group or placebo effect group) every week. The ultimate goal of the scientific research was to treat renal tubular filtration rate (EGFR), urinary albumin to creatinine ratio (UACR) and The role of adverse reactions in renal function.

In suppine1-5 and suppine7 scientific studies, after 12 weeks of continuous injection of semaluptide, the renal tubular filtration rate was significantly improved. Compared with placebo effect, the estimated treatment difference (ETDs) of EGFR in 0.5mg semaluptide group was -2.15ml/minper1.73m2, and that of 1.0mg semaluptide group was -3.00ml/minper1.73m2.

In suppine1-5 and suppine7 scientific studies, ETDs of 0.5mg semaluptide group was -1.58ml/minper1.73m2, and that of 1.0mg semaluptide group was -2.02ml/minper1.73m2. In sustain6, at 16 weeks, compared with placebo effect, ETDs of 0.5mg semaluptide group was -1.29ml/minper1.73m2, and that of 1.0mg semaluptide group was -1.56ml/minper1.73m2, but at 16-104 weeks, compared with placebo effect, the effect of semaluptide on EGFR was reduced.

However, in sustain6, semaluptide had no significant effect on EGFR. In suppine1-5, until the end of the experiment, the UACR of the 0.5mg semaluptide group was 0.917, that of the 1.0mg semaluptide group was 0.836, and that of the placebo effect group was 1.239. In the sustain6 scientific study, by 104 weeks, the UACR of 0.5mg semaluptide group was 0.973, that of 1.0mg semaluptide group was 0.858, and that of placebo effect group was 1.302. Semaluptide had significant effect on reducing UACR (the estimated cure rate of 0.5mg and 1.0mg somaluptide groups were 0.75 and 0.66 respectively).

In the sustain1-7 scientific study, EGFR decreased first in patients with normal renal function who received semaluptide, but on the whole, there was no significant difference between semaluptide and placebo. In sustain1-6 scientific research, for patients with previous microalbuminuria or albuminuria protein, UACR decreased after semaluptide injection for a period of time, but it had no effect on all normal urine protein groups. There was no significant difference in renal adverse reactions between groups.

Scientific researchers believe that for patients with type II diabetes, semaluptide treatment has no significant effect on renal tubular filtration rate, but can significantly reduce the ratio of urinary albumin to creatinine, and does not increase the risk of adverse reactions to renal function.

For any requests of Peptide for research purpose, welcome to contact us. www.gtpeptide.com , sales1@gotopbio.com.